Biologically informed deep neural network for prostate cancer discovery

The determination of molecular features that mediate clinically aggressive phenotypes in prostate cancer remains a major biological and clinical challenge 1 , 2 . Recent advances in interpretability of machine learning models as applied to biomedical problems may enable discovery and prediction in c...

Full description

Saved in:
Bibliographic Details
Published inNature (London) Vol. 598; no. 7880; pp. 348 - 352
Main Authors Elmarakeby, Haitham A., Hwang, Justin, Arafeh, Rand, Crowdis, Jett, Gang, Sydney, Liu, David, AlDubayan, Saud H., Salari, Keyan, Kregel, Steven, Richter, Camden, Arnoff, Taylor E., Park, Jihye, Hahn, William C., Van Allen, Eliezer M.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 14.10.2021
Nature Publishing Group
Subjects
Online AccessGet full text
ISSN0028-0836
1476-4687
1476-4687
DOI10.1038/s41586-021-03922-4

Cover

More Information
Summary:The determination of molecular features that mediate clinically aggressive phenotypes in prostate cancer remains a major biological and clinical challenge 1 , 2 . Recent advances in interpretability of machine learning models as applied to biomedical problems may enable discovery and prediction in clinical cancer genomics 3 – 5 . Here we developed P-NET—a biologically informed deep learning model—to stratify patients with prostate cancer by treatment-resistance state and evaluate molecular drivers of treatment resistance for therapeutic targeting through complete model interpretability. We demonstrate that P-NET can predict cancer state using molecular data with a performance that is superior to other modelling approaches. Moreover, the biological interpretability within P-NET revealed established and novel molecularly altered candidates, such as MDM4 and FGFR1 , which were implicated in predicting advanced disease and validated in vitro. Broadly, biologically informed fully interpretable neural networks enable preclinical discovery and clinical prediction in prostate cancer and may have general applicability across cancer types. A biologically informed, interpretable deep learning model has been developed to evaluate molecular drivers of resistance to cancer treatment, predict clinical outcomes and guide hypotheses on disease progression.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0028-0836
1476-4687
1476-4687
DOI:10.1038/s41586-021-03922-4